Dutch Biotech Kiadis Closes $5.2M Series B For Growth

Dutch drug discovery firm Kiadis BV said it had closed a EUR4 million ($5.2
million) in Series B financing round to fund technology advancement and the
identification of key compounds, especially kinases.